Home › Cervical Cancer › NCT04857528
Detecting HPV DNA in Anal and Cervical Cancers
Circulating HPV DNA in Cancers of the Anus and Uterine Cervix Treated With Definitive Radiation Therapy
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Stage I-III anal cancer or stage I-IVA cervical cancer that is p16+ based on immunohistochemistry. * Age ≥ 18 years * Planned to undergo radiation therapy as definitive treatment, with or without concurrent systemic therapy Exclusion Criteria: * Anal carcinoma not associated with HPV-16, 18, 31, 33, or 35 will be removed from the * Planned to undergo radiation therapy as an adjuvant or post-operative therapy
About the study
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more information about HPV-associated cancers and how they respond to treatment. Participation in this study will last approximately 2 years.
What is being tested
- Radiation Treatment With or Without Chemotherapy (radiation)
- Blood Sample Collection (other)
- HPV Genotyping (HPV DNA Test) (diagnostic test)
- Testing Archival Tumor Tissue (diagnostic test)
- Physical Exam (other)
- Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan) (diagnostic test)
Sponsor: University of Chicago · Participants: 20 · Started: Oct 6, 2020
Contact the study team
- Christina Son, MD · Phone: 773-702-6870
Official record on ClinicalTrials.gov — NCT04857528
Locations in the U.S.
| Illinois | University of Chicago, Chicago University of Illinois at Chicago, Chicago |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.